MARCH2: Comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patients

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Wang, Guang ^a   Liu, Jia ^a   Yang, Ning ^a   Gao, Xia ^a   Fan, Hui ^a   Xu, Yuan ^a   Yang, Wenying ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSIDASE INHIBITOR;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; BODY WEIGHT; CHINESE; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HIP CIRCUMFERENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WAIST CIRCUMFERENCE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TIME FACTOR;

ACARBOSE; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FASTING; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; TIME FACTORS;

EID: 84939803950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105698     Document Type: Article

References (37)

1. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369: 145-154.
2. Freeman JS (2013) Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors. Postgrad Med 125: 214-226.
3. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, et al. (2009) American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 32: 1119-1131.
4. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, et al. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486-494. (Pubitemid 37430502)
5. Lamanna C, Monami M, Marchionni N, Mannucci E (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13: 221-228.
6. Wenying Y, Jie L, Zhongyan S, Haoming T, Zhiguang Z, et al. (2014) Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomized trial. Lancet Diabetes Endocrinol 2: 46-55.
7. Miller M, Ginsberg HN, Schaefer EJ (2008) Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 101: 1003-1008.
8. Grundy SM (2013) An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J Clin Lipidol 7: 561-565.
9. Bermudez V, Cano R, Cano C, Bermudez F, Leal E, et al. (2008) Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes. Am J Ther 15: 409-416.
10. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, et al. (2001) Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 24: 362-365. (Pubitemid 32119139)
11. Yangfeng W, Beifan Z, Shouqi T, Xigui W, Jun Y, et al. (2002) Prevalence of overweight and obesity in Chinese middle-aged populations: Current status and trend of development. Chin J Epidemiol 23: 5-10.
12. Hanefeld M (2007) Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol 6: 20.
13. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, et al. (1996) The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 19: 920-926. (Pubitemid 26301225)
14. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403. (Pubitemid 34437694)
15. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, et al. (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25: 10-16. (Pubitemid 38055587)
16. Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damci T, et al. (2011) Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 96: 3337-3353.
17. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, et al. (2001) Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50: 856-861. (Pubitemid 32700469)
18. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, et al. (2001) Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24: 489-494. (Pubitemid 32198418)
19. Kim SH, Reaven G (2013) Sex differences in insulin resistance and cardiovascular disease risk. J Clin Endocrinol Metab 98: 1716-1721.
20. Rojas LB, Gomes MB (2013) Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 5: 6.
21. Salman ZK, Refaat R, Selima E, El Sarha A, Ismail MA (2013) The combined effect of metformin and L-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats. Eur J Pharmacol 714: 448-455.
22. Zhai J, Liu CX, Tian ZR, Jiang QH, Sun YP (2012) Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. Biol Reprod 87: 29.
23. Azuma K, Toyofuku Y, Iesaki T, Otsuka A, Tanaka A, et al. (2006) Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res Commun 345: 688-693. (Pubitemid 43776986)
24. Zhang W, Zhao S, Li Y, Peng G, Han P (2013) Acute blood glucose fluctuation induces myocardial apoptosis through oxidative stress and nuclear factor-kB activation. Cardiology 124: 11-17.
25. Karamanos B, Thanopoulou A, Drossinos V, Charalampidou E, Sourmeli S, et al. (2011) Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA). Curr Med Res Opin 27: 303-313.
26. Aghahosseini M, Aleyaseen A, Safdarian L, Moddaress-Hashemi S, Mofid B, et al. (2010) Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile. Arch Gynecol Obstet 282: 691-694.
27. Quintero-Castillo D, Luz-Araujo H, Guerra-Velazquez M, Reyna-Villasmil E, Santos Bolivar J, et al. (2010) Lipid profile in obese and non-obese women with polycystic ovary syndrome treated with metformin. Endocrinol Nutr 57: 262-267.
28. Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, et al. (2012) Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther 29: 736-746.
29. Jensen MD, Nielsen S (2007) Insulin dose response analysis of free fatty acid kinetics. Metabolism 56: 68-76. (Pubitemid 44855014)
30. Rosenbaum P, Peres RB, Zanella MT, Ferreira SR (2002) Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. Braz J Med Biol Res 35: 877-884. (Pubitemid 35390339)
31. Kaiser T, Sawicki PT (2004) Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. Diabetologia 47: 575-580. (Pubitemid 38491258)
32. He H, Zhao Z, Chen J, Ni Y, Zhong J, et al. (2012) Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. J Hypertens 30: 1430-1439.
33. Uehara MH, Kohlmann NE, Zanella MT, Ferreira SR (2001) Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab 3: 319-325. (Pubitemid 33072212)
34. Verma S, Yao L, Dumont AS, McNeill JH (2000) Metformin treatment corrects vascular insulin resistance in hypertension. J Hypertens 18: 1445-1450.
35. Zheng Z, Chen H, Li J, Li T, Zheng B, et al. (2012) Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 61: 217-228.
36. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, et al. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120: 2355-2369.
37. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, et al. (2008) SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 21: 507-511. (Pubitemid 351802646)